Desmopressin increases risk for hyponatremia.

Today i recieve a article from Doctor's Guide regarding Desmopressin and i want to share with healthcare professionals.
Health Canada is informing healthcare professionals that all intranasal formulations of desmopressin (DDAVP) are no longer indicated for the treatment of primary nocturnal enuresis (PNE) due to an increased risk of hyponatremia with the intranasal formulations.· All intranasal formulations of desmopressin are now contraindicated for the treatment of PNE.· All patients using intranasal formulations of desmopressin for treatment of PNE should be reassessed to determine their need for continued treatment and to discuss other options.
If ongoing treatment is considered necessary, patients should be switched to the lowest starting dose of an oral formulation, with the dose increased only if necessary to control symptoms.
Fluid intake and desmopressin dosage should be adjusted carefully in order to reduce the possibility of water retention and hyponatremia, especially in very young and elderly patients or when significant daily variables occur such as hot climate conditions, intense exercise, or other situations where increased water intake can be expected.
Worldwide postmarketing data indicate a higher incidence of hyponatremia in patients being treated with the desmopressin intranasal formulations compared with the oral formulations.
When desmopressin treatment is needed, physicians should discuss with the patient and/or guardian the importance of limiting the amount of fluid intake 1 hour before taking the medication and during the 8 hours postdose.
SOURCE: Health Canada

Comments

Popular posts from this blog

Treatment Guidelines for Malaria Contd...

Basics of Oral Anti-diabetic drugs

Ranexa